PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...
Cancer
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...
CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment
The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision...
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...
Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study
China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...
Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH
Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...
Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma
China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...
Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics
China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...
Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA
China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...
Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...
Baidu Health Partners with Shanghai Epiprobe for Cancer Early Screening
China Internet giant Baidu’s Health Internet Hospital unit has announced a partnership with Shanghai Epiprobe...
Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...
Antengene’s ATG-017 Gets FDA Approval for Phase I Clinical Study
Antengene Corporation has announced receiving approval from the US Food and Drug Administration (FDA) to...
Eucure Biopharma Partners with ISU ABXIS to Develop Tri-Specific Antibodies Using YH003
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...
Simcere’s SIM0235 Begins US Phase I Trial for Anti-Tumor Therapy
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the enrollment of the first patient in...